(Q35249636)

English

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Maxime Dougados

14

object named as

Maxime Dougados

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Michael Schiff

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mauro Keiserman

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Christine Codding

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Suthin Songcharoen

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Alberto Berman

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sauithree Nayiager

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Cristina Saldate

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Richard Aranda

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jean-Claude Becker

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Marleen Nys

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Manuela le Bars

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Diane Moniz Reed

12

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Coralie Poncet

13

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

12 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2003-2007

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

The Disease Activity Score and the EULAR response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

12 July 2018

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

26 September 2018

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

26 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

26 September 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3184243

26 September 2018

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21914628

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2011-200316

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35249636&oldid=1575791287"